Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

Diabetes, Obesity and Metabolism

Volumn 16, Issue 9, 2014, Pages 873-876

  Steinstraesser, A ^a   Schmidt, R ^a   Bergmann, K ^a   Dahmen, R ^a   Becker, R H A ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Insulin analogues; Pharmacokinetics; Type 1 diabetes

Indexed keywords

DRUG METABOLITE; INSULIN GLARGINE; NEW DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; EUGLYCEMIC CLAMP; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LIQUID CHROMATOGRAPHY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TANDEM MASS SPECTROMETRY; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; TREATMENT OUTCOME;

BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUGS, INVESTIGATIONAL; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; TREATMENT OUTCOME;

EID: 84905721701     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12283     Document Type: Article

References (12)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
2. Dahmen R, Bergmann K, Lehmann A et al. New insulin glargine U300 formulation evens and prolongs steady state PK and PD profiles during euglycemic clamp in patients with type 1 diabetes (T1DM) [abstract]. Diabetes 2013; 62(Suppl. 2): A29.
3. Monti LD, Poma R, Caumo A et al. Intravenous infusion of diarginylinsulin, an insulin analogue: effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients. Metabolism 1992; 41: 540-544.
4. Kuerzel GU, Shukla U, Scholtz HE et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003; 19: 34-40.
5. Bolli GB, Hahn AD, Schmidt R et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care 2012; 35: 2626-2630.
6. Lucidi P, Porcellati F, Rossetti P et al. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. Diabetes Care 2011; 34: 1312-1314.
7. Sommerfeld MR, Muller G, Tschank G et al. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One 2010; 5: e9540.
8. Expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998; 21(Suppl. 1): S5-S19.
9. Hauck WW, Tozer TN, Anderson S, Bois FY. Considerations in the attainment of steady state: aggregate vs. individual assessment. Pharm Res 1998; 15: 1796-1798.
10. Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328.
11. Fagot JP, Blotiere PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases. Diabetes Care 2013; 36: 294-301.
12. Grimaldi-Bensouda L, Cameron D, Marty M et al. Risk of breast cancer by individual insulin use: an international multicenter study. Diabetes Care 2014; 37: 134-143.